SCHEMBL2376148

SCHEMBL2376148

COC(=O)C(Cc1ccnn1C)NCc1ccc(-c2ccncc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPID Q08752 1/20 0.41
GPR142 Q7Z601 7/20 0.40
LCK P06239 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SIRT2 Q8IXJ6 1/20 0.38
HDAC1 Q13547 5/20 0.37
HDAC6 Q9UBN7 4/20 0.36
ROCK2 O75116 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
PRKACA P17612 1/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
PRKX P51817 1/20 0.36
PRKCQ Q04759 1/20 0.36
ROCK1 Q13464 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
CLK1 P49759 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2375304 0.84 EPHX1 (0.42) GPR142L3MBTL1SIRT2HDAC1HDAC6
SCHEMBL2374193 0.83 PPID (0.42) PPIDGPR142LCKKMT2AL3MBTL1
SCHEMBL2374570 0.80 PPID (0.48) PPIDGPR142HDAC1ROCK2CYP3A4
SCHEMBL2374561 0.80 PPID (0.48) PPIDGPR142HDAC1ROCK2CYP3A4
SCHEMBL2375909 0.79 GPR142 (0.47) PPIDGPR142SIRT2HDAC1ROCK2
SCHEMBL2374062 0.74 PPID (0.44) PPIDGPR142SIRT2HDAC1ROCK2
SCHEMBL2374058 0.74 PPID (0.44) PPIDGPR142SIRT2HDAC1ROCK2
SCHEMBL2373510 0.70 PPID (0.50) PPIDGPR142HDAC1ROCK2CYP3A4
SCHEMBL1356569 0.70 KMT2A (0.46) KMT2AL3MBTL1
SCHEMBL2374130 0.70 PPID (0.47) PPIDGPR142KMT2AHDAC1ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS CTSA, BECN1, HDAC6 PPID 654/4885GPR142 3414/4885LCK 3863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.